Wordt geladen...
BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
The treatment landscape in advanced melanoma is changing dramatically with the approval of new drugs. Vemurafenib was the first approved targeted agent for the treatment of BRAF-mutant advanced melanoma. However, treatment with a BRAF inhibitor is linked with acquired resistance occurring in half of...
Bewaard in:
| Gepubliceerd in: | Contemp Oncol (Pozn) |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Termedia Publishing House
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885075/ https://ncbi.nlm.nih.gov/pubmed/29628797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2018.73890 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|